Source: Pharmacy Times articles
Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma.
Read More
by | Apr 11, 2024 | Myeloma News | 0 comments
Source: Pharmacy Times articles
Venetoclax, which is approved for leukemia, blocks a function of the BCL-2 protein and has previously shown efficacy in a small proportion of patients with multiple myeloma.
Read More